EA201590773A1 - Способ диагностики для прогнозирования ответа на ингибитор фактора некроза опухоли альфа (tnf альфа) - Google Patents

Способ диагностики для прогнозирования ответа на ингибитор фактора некроза опухоли альфа (tnf альфа)

Info

Publication number
EA201590773A1
EA201590773A1 EA201590773A EA201590773A EA201590773A1 EA 201590773 A1 EA201590773 A1 EA 201590773A1 EA 201590773 A EA201590773 A EA 201590773A EA 201590773 A EA201590773 A EA 201590773A EA 201590773 A1 EA201590773 A1 EA 201590773A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alpha
necrosis factor
tumor necrosis
predicting
inhibitor
Prior art date
Application number
EA201590773A
Other languages
English (en)
Other versions
EA037105B1 (ru
Inventor
Ласло Надь
Берталан Мешко
Ласло Штеинер
Габор Захуцки
Жольт Холло
Original Assignee
Эгиш Дьёдьсердьяр Зрт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эгиш Дьёдьсердьяр Зрт. filed Critical Эгиш Дьёдьсердьяр Зрт.
Publication of EA201590773A1 publication Critical patent/EA201590773A1/ru
Publication of EA037105B1 publication Critical patent/EA037105B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Раскрыты способы диагностики in vitro для прогнозирования того, будет ли пациент отвечать на лечение ингибитором TNFα (фактор некроза опухоли альфа). Указанный способ основан на профилировании экспрессии генов. Путем измерения профиля экспрессии раскрытых генов возможно прогнозировать, будет ли успешным лечение ингибитором TNFα или нет.
EA201590773A 2012-10-19 2013-10-18 Способ диагностики для прогнозирования ответа на ингибитор фактора некроза опухоли альфа (tnf) EA037105B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1200607A HU230680B1 (hu) 2012-10-19 2012-10-19 Diagnosztikai eljárás
PCT/HU2013/000101 WO2014060785A2 (en) 2012-10-19 2013-10-18 DIAGNOSTIC METHOD FOR PREDICTING RESPONSE TO TNFα INHIBITOR

Publications (2)

Publication Number Publication Date
EA201590773A1 true EA201590773A1 (ru) 2015-09-30
EA037105B1 EA037105B1 (ru) 2021-02-05

Family

ID=89990915

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590773A EA037105B1 (ru) 2012-10-19 2013-10-18 Способ диагностики для прогнозирования ответа на ингибитор фактора некроза опухоли альфа (tnf)

Country Status (12)

Country Link
US (1) US20160194709A1 (ru)
EP (1) EP2909340B1 (ru)
JP (1) JP2016502400A (ru)
CA (1) CA2889087C (ru)
DK (1) DK2909340T3 (ru)
EA (1) EA037105B1 (ru)
ES (1) ES2645972T3 (ru)
HU (1) HU230680B1 (ru)
NO (1) NO2909340T3 (ru)
PL (1) PL2909340T3 (ru)
UA (1) UA118658C2 (ru)
WO (1) WO2014060785A2 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179469A1 (en) * 2015-05-07 2016-11-10 Abbvie Inc. Methods and compositions for diagnosing and treating inflammatory bowel disease
JP2018527895A (ja) 2015-06-29 2018-09-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法
GB2547406A (en) * 2015-11-20 2017-08-23 Folkersen Lasse Apparatus and methods of using of biomarkers for predicting TNF-inhibitor response
GB201521357D0 (en) * 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
EP3433271A4 (en) * 2016-03-23 2019-11-27 Regents of the University of Minnesota PROCEDURE FOR DETECTING APOBEC3 EXPRESSION AND PREDICTING CLINICAL RESULTS
US20200399698A1 (en) * 2018-02-19 2020-12-24 Genefron Ltd. Methods of determining response to tnf alpha blockers
EP3765634A4 (en) 2018-03-16 2021-12-01 Scipher Medicine Corporation METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE TO ANTI-TNF THERAPIES
WO2020111887A1 (ko) * 2018-11-30 2020-06-04 차의과학대학교 산학협력단 뇌 유래 소포체 특이적 마커 및 이를 이용한 뇌 질병 진단 방법
US20220073988A1 (en) * 2018-12-07 2022-03-10 Dna Chip Research Inc. Method for predicting efficacy of rheumatoid arthritis therapeutic agent and biomarker used therein
WO2020264426A1 (en) 2019-06-27 2020-12-30 Scipher Medicine Corporation Developing classifiers for stratifying patients
KR102429261B1 (ko) * 2020-08-25 2022-08-03 충북대학교 산학협력단 한국인의 tnf 저해제 약물 반응성 예측을 위한 바이오마커

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058362A1 (en) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
ES2322267T3 (es) * 2003-04-09 2009-06-18 Genentech, Inc. Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa.
EP1857559A1 (en) * 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
WO2008122007A1 (en) * 2007-04-02 2008-10-09 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
WO2008132176A2 (en) * 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
US8092998B2 (en) * 2007-05-31 2012-01-10 Abbott Laboratories Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
CN102171365B (zh) * 2008-08-25 2014-01-29 森托科尔奥索生物科技公司 用于溃疡性结肠炎和相关疾病的抗tnf治疗的生物标记物
JP2011004743A (ja) * 2009-06-26 2011-01-13 Dna Chip Research Inc 関節リウマチ患者におけるインフリキシマブ薬効の有効性を判別する方法
WO2012061620A1 (en) * 2010-11-04 2012-05-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis

Also Published As

Publication number Publication date
WO2014060785A3 (en) 2014-06-12
UA118658C2 (uk) 2019-02-25
DK2909340T3 (da) 2017-11-13
CA2889087A1 (en) 2014-04-24
ES2645972T3 (es) 2017-12-11
WO2014060785A2 (en) 2014-04-24
EP2909340B1 (en) 2017-08-02
EA037105B1 (ru) 2021-02-05
JP2016502400A (ja) 2016-01-28
US20160194709A1 (en) 2016-07-07
PL2909340T3 (pl) 2018-01-31
CA2889087C (en) 2021-11-16
NO2909340T3 (ru) 2017-12-30
HU230680B1 (hu) 2017-08-28
HUP1200607A2 (en) 2014-04-28
EP2909340A2 (en) 2015-08-26

Similar Documents

Publication Publication Date Title
EA201590773A1 (ru) Способ диагностики для прогнозирования ответа на ингибитор фактора некроза опухоли альфа (tnf альфа)
MX363584B (es) Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2.
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
WO2014085826A3 (en) Method for evaluation of presence of or risk of colon tumors
MX2016012697A (es) Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
MX365421B (es) Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf.
MX2014006182A (es) Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr.
NZ630421A (en) Biomarkers predictive for clinical response for glatiramer acetate
NZ629538A (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
EP4265740A3 (en) Methods for predicting risk of metastasis in cutaneous melanoma
MX2013011334A (es) Biomarcadores para pronosticar sensibilidad a tratamientos contra el cancer.
MX358730B (es) Metodos para predecir y monitorear cicatrizacion de la mucosa.
GB2480980A (en) Methods for predicting cancer response to EGFR inhibitors
MX2019013953A (es) Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.
EP3798316A3 (en) Genes and gene signatures for diagnosis and treatment of melanoma
EA201590495A1 (ru) Способ диагностики и лечения рака, направленный на молекулы, экспрессируемые в раковых стволовых клетках
MX2017003832A (es) Metodo para la prediccion de sensibilidad a un tratamiento con un inhibidor de egfr.
EA201501137A1 (ru) Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac
WO2014023808A3 (en) Method for evaluating a cancer patient for propensity to respond to a therapy
WO2015181555A8 (en) Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent
MX364003B (es) Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4.
GB2505833A (en) Assessment method
MX2014015826A (es) Metodo pronostico de la respuesta al tratamiento estandar en cancer cervicouterino localmente avanzado.